Teton Advisors’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-22,000
Closed -$491K 280
2022
Q2
$491K Hold
22,000
0.1% 199
2022
Q1
$552K Hold
22,000
0.1% 221
2021
Q4
$788K Hold
22,000
0.11% 209
2021
Q3
$936K Hold
22,000
0.14% 186
2021
Q2
$952K Hold
22,000
0.13% 192
2021
Q1
$897K Hold
22,000
0.13% 197
2020
Q4
$996K Hold
22,000
0.14% 192
2020
Q3
$779K Hold
22,000
0.13% 192
2020
Q2
$830K Buy
22,000
+6,000
+38% +$198K 0.13% 195
2020
Q1
$463K Buy
16,000
+11,000
+220% +$445K 0.08% 270
2019
Q4
$259K Sell
5,000
-5,000
-50% -$290K 0.03% 398
2019
Q3
$549K Sell
10,000
-30,000
-75% -$1.54M 0.06% 315
2019
Q2
$1.63M Hold
40,000
0.16% 172
2019
Q1
$1.21M Hold
40,000
0.12% 204
2018
Q4
$1.34M Buy
40,000
+7,000
+21% +$253K 0.15% 181
2018
Q3
$1.39M Buy
33,000
+16,000
+94% +$632K 0.12% 199
2018
Q2
$544K Buy
+17,000
New +$700K 0.05% 311

Other funds holding ANIK

Teton Advisors's ANIK Position: Q3 2022 in Review

Teton Advisors sold out of Anika Therapeutics (ANIK) in Q3 2022, closing a stake of 22,000 shares — an estimated $491K sold.

Teton Advisors first reported a position in ANIK in Q2 2018 and held it in 17 quarters. The position peaked at $1.63M in Q2 2019. 121 funds tracked by Wall St. Rank hold ANIK as of Q3 2022.

  • Teton Advisors reported no remaining Anika Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Teton Advisors sold 22,000 Anika Therapeutics shares in Q3 2022, an estimated $491K.
  • Teton Advisors first reported a position in Anika Therapeutics in Q2 2018 and held it in 17 quarters.
  • Teton Advisors's Anika Therapeutics position peaked at $1.63M in Q2 2019.
  • 121 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2022.

Based on Teton Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.